Journal of Clinical Oncology, Vol 8, 1894-1906, Copyright © 1990 by American Society of Clinical Oncology
Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33
S Welt, CR Divgi, FX Real, SD Yeh, P Garin-Chesa, CL Finstad, J Sakamoto, A Cohen, ER Sigurdson and N Kemeny
Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
A33 is a mouse immunoglobulin G2a (IgG2a) monoclonal antibody (mAb) that
detects a heat-stable, protease- and neuraminidase-resistant epitope. The
antigen is homogeneously expressed by virtually all colon cancers and in
the colon mucosa but not other epithelial tissues. The biodistribution and
imaging characteristics of iodine-131 (131I)-mAbA33 were studied in
colorectal carcinoma patients with hepatic metastases. Antibody labeled
with 2 to 5 mCi of 131I was administered intravenously (IV) 7 to 8 days
before surgery at five dose levels, ranging from 0.2 mg to 50 mg, with
three or more patients entered at each dose level. In addition, three
patients received 2 mg 131I-mAbTA99 (an isotype-matched control mAb)
together with 125I-mAbA33. Evaluation included whole-body imaging with a
gamma camera, technetium-99 (99mTc)-human serum albumin blood pool scans,
liver/spleen scans, abdominal computed tomographic (CT) scans, hepatic
arteriograms, antibody pharmacokinetics, and assessment of antibody
distribution in biopsied malignant and normal tissues. Selective mAbA33
localization to tumor tissue was demonstrated in 19 of 20 patients, and
external imaging correlated with surgical inspection, pathologic
examination, and tissue radioactivity. One week after antibody
administration, tumor:liver ratios ranged from 6.9:1 to 100:1 and
tumor:serum ratios from 4.1:1 to 25.2:1. 99mTc-albumin blood pool studies
showed that liver metastases were hypovascular, emphasizing the selective
localization of mAbA33 despite poor tumor- blood flow. Control mAbTA99
studies showed mAbA33 localization was antigen-specific; tumor:liver ratios
were 2.3- to 45-fold higher for specific antibody. In metastatic lesions,
radioisotope was localized primarily in the viable periphery; however, even
the necrotic tumor core concentrated specific antibody. External imaging
showed isotope visualization in some patients' large bowel; whether this
represents specific antibody uptake or gastric iodine secretion is unclear.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
E. G. Cafferata, D. R. Maccio, M. V. Lopez, D. L. Viale, C. Carbone, G. Mazzolini, and O. L. Podhajcer
A Novel A33 Promoter-Based Conditionally Replicative Adenovirus Suppresses Tumor Growth and Eradicates Hepatic Metastases in Human Colon Cancer Models
Clin. Cancer Res.,
May 1, 2009;
15(9):
3037 - 3049.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Ackerman, D. Pawlowski, and K. D. Wittrup
Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids
Mol. Cancer Ther.,
July 1, 2008;
7(7):
2233 - 2240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ychou, D. Azria, C. Menkarios, P. Faurous, F. Quenet, B. Saint-Aubert, P. Rouanet, M. Pelegrin, C. Bascoul-Mollevi, D. Guerreau, et al.
Adjuvant Radioimmunotherapy Trial with Iodine-131-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody F6 F(ab')2 after Resection of Liver Metastases from Colorectal Cancer
Clin. Cancer Res.,
June 1, 2008;
14(11):
3487 - 3493.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Petrausch, J. Dernedde, V. Coelho, H. Panjideh, D. Frey, H. Fuchs, E. Thiel, and P. M. Deckert
A33scFv Green fluorescent protein, a recombinant single-chain fusion protein for tumor targeting
Protein Eng. Des. Sel.,
December 1, 2007;
20(12):
583 - 590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Scott, F.-T. Lee, N. Tebbutt, R. Herbertson, S. S. Gill, Z. Liu, E. Skrinos, C. Murone, T. H. Saunder, B. Chappell, et al.
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
PNAS,
March 6, 2007;
104(10):
4071 - 4076.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Scott, F.-T. Lee, R. Jones, W. Hopkins, D. MacGregor, J. S. Cebon, A. Hannah, G. Chong, P. U, A. Papenfuss, et al.
A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake
Clin. Cancer Res.,
July 1, 2005;
11(13):
4810 - 4817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Chong, F. T. Lee, W. Hopkins, N. Tebbutt, J. S. Cebon, A. J. Mountain, B. Chappell, A. Papenfuss, P. Schleyer, P. U, et al.
Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma
Clin. Cancer Res.,
July 1, 2005;
11(13):
4818 - 4826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. He, H. Lu, P. Siddiqui, Y. Zhou, and S. Jiang
Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains Multiple Conformation-Dependent Epitopes that Induce Highly Potent Neutralizing Antibodies
J. Immunol.,
April 15, 2005;
174(8):
4908 - 4915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Raschperger, U. Engstrom, R. F. Pettersson, and J. Fuxe
CLMP, a Novel Member of the CTX Family and a New Component of Epithelial Tight Junctions
J. Biol. Chem.,
January 2, 2004;
279(1):
796 - 804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Welt, G. Ritter, C. Williams Jr., L. S. Cohen, M. John, A. Jungbluth, E. A. Richards, L. J. Old, and N. E. Kemeny
Phase I Study of Anticolon Cancer Humanized Antibody A33
Clin. Cancer Res.,
April 1, 2003;
9(4):
1338 - 1346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Welt, G. Ritter, C. Williams Jr., L. S. Cohen, A. Jungbluth, E. A. Richards, L. J. Old, and N. E. Kemeny
Preliminary Report of a Phase I Study of Combination Chemotherapy and Humanized A33 Antibody Immunotherapy in Patients with Advanced Colorectal Cancer
Clin. Cancer Res.,
April 1, 2003;
9(4):
1347 - 1353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ritter, L. S. Cohen, C. Williams Jr., E. C. Richards, L. J. Old, and S. Welt
Serological Analysis of Human Anti-Human Antibody Responses in Colon Cancer Patients Treated with Repeated Doses of Humanized Monoclonal Antibody A33
Cancer Res.,
September 1, 2001;
61(18):
6851 - 6859.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Barendswaard, J. L. Humm, J. A. O'Donoghue, G. Sgouros, R. D. Finn, A. M. Scott, S. M. Larson, and S. Welt
Relative Therapeutic Efficacy of 125I- and 131I-Labeled Monoclonal Antibody A33 in a Human Colon Cancer Xenograft
J. Nucl. Med.,
August 1, 2001;
42(8):
1251 - 1256.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. N. Johnstone, N. C. Tebbutt, H. E. Abud, S. J. White, K. L. Stenvers, N. E. Hall, S. H. Cody, R. H. Whitehead, B. Catimel, E. C. Nice, et al.
Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells
Am J Physiol Gastrointest Liver Physiol,
September 1, 2000;
279(3):
G500 - G510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Pai-Scherf, J. A. Carrasquillo, C. Paik, O. Gansow, M. Whatley, D. Pearson, K. Webber, M. Hamilton, C. Allegra, M. Brechbiel, et al.
Imaging and Phase I Study of 111In- and 90Y-labeled Anti-LewisY Monoclonal Antibody B3
Clin. Cancer Res.,
May 1, 2000;
6(5):
1720 - 1730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rader, G. Ritter, S. Nathan, M. Elia, I. Gout, A. A. Jungbluth, L. S. Cohen, S. Welt, L. J. Old, and C. F. Barbas III
The Rabbit Antibody Repertoire as a Novel Source for the Generation of Therapeutic Human Antibodies
J. Biol. Chem.,
April 28, 2000;
275(18):
13668 - 13676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Sobocka, T. Sobocki, P. Banerjee, C. Weiss, J. I. Rushbrook, A. J. Norin, J. Hartwig, M. O. Salifu, M. S. Markell, A. Babinska, et al.
Cloning of the human platelet F11 receptor: a cell adhesion molecule member of the immunoglobulin superfamily involved in platelet aggregation
Blood,
April 15, 2000;
95(8):
2600 - 2609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Heath, S. J. White, C. N. Johnstone, B. Catimel, R. J. Simpson, R. L. Moritz, G.-F. Tu, H. Ji, R. H. Whitehead, L. C. Groenen, et al.
The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily
PNAS,
January 21, 1997;
94(2):
469 - 474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Catimel, G. Ritter, S. Welt, L.J. Old, L. Cohen, M.A. Nerrie, S.J. White, J.K. Heath, B. Demediuk, T. Domagala, et al.
Purification and Characterization of a Novel Restricted Antigen Expressed by Normal and Transformed Human Colonic Epithelium
J. Biol. Chem.,
October 11, 1996;
271(41):
25664 - 25670.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
